Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although
there are many possible treatments, including targeted therapies such as epidermal growth …

Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer
outside of clinical trials. Early trials with vaccines yielded promising results, but phase III …

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer‐
related deaths in China. The recent emergence of immunotherapy treatment options, such …

The three major conventional treatments: surgery, chemotherapy, and radiation therapy,
have been commonly performed for lung cancer. However, lung cancer is still the leading …

Immune checkpoint inhibitors in first-line therapy of advanc... : Current Opinion in Oncology
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer …

Immune checkpoint inhibition as a new treatment approach is undergoing extensive
investigation in non–small cell lung cancer (NSCLC) and other malignancies. Unlike …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Background The introduction of immunotherapy in the treatment of non-small cell lung
cancer (NSCLC) has resulted in a radical change in patients' treatment responses and …

Lung cancer is the leading cause of cancer-related mortality worldwide. Treatment with
immunotherapy has made a significant impact on the outcomes for those patients suffering …